IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (NCT05987332)
IDE196-002
This trial is No longer recruiting
Registration number NCT05987332
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Mark Shackleton
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR